An Open-label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs RG 7598 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Genentech
- 08 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Feb 2014 Planned End Date changed from 1 Nov 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov.
- 13 Aug 2013 Planned end date changed from 1 Jan 2016 to 1 Nov 2015 as reported by ClinicalTrials.gov.